Please login to the form below

Not currently logged in
Email:
Password:

CAR T cell therapy

This page shows the latest CAR T cell therapy news and features for those working in and with pharma, biotech and healthcare.

University of Strathclyde develops pre-clinical screening tool which could increase cancer test numbers by up to 50 times

University of Strathclyde develops pre-clinical screening tool which could increase cancer test numbers by up to 50 times

The screening tool enables large-scale testing of the latest immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, a treatment effective against many haematological cancers but one that presents ... CAR-T cell development is expensive

Latest news

More from news
Approximately 3 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world

    EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR T-cell therapy and rare diseases. ... These visuals got the message across in an engaging, novel and efficient manner

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... We estimate the cost [of making a CAR-T cell therapy for a single

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

  • Deal Watch October 2018

    Cell therapy products based on antigen presenting cells. for target‐specific killer CD8 T‐cell responses. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    He is part of a team using a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy, which is transforming outcomes for children who would otherwise have no treatment options left. ... SA: CAR-T cell therapy is an innovative immunotherapy that

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US. ... The approach is to deliver treatments which restore or establish normal cell

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....